Francesca Bryn Walker, PA-C

Francesca Walker practices at Dermatologic Center For Excellence in Clarence, New York.

Francesca Walker's NPI, 1306574595, was assigned on August 15, 2022. Francesca Walker holds New York license 028438-01.

Francesca Walker's primary practice is Dermatologic Center for Excellence, at 9276 Main St Suite 1a Suite 1a, Clarence, NY 14031-1969. The practice phone is (716) 759-7759.

Francesca Walker's primary practice is Dermatologic Center For Excellence in Clarence, New York. The medical group on file is Dermatologic Center for Excellence.

Dmand AI tracks the electronic health record (EHR) system at each site where Francesca Walker practices. Vendor and product names are available with a free account.

Physician assistant is Francesca Walker's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Francesca Walker is licensed in New York.

Dmand AI lists acne, benign or precancerous skin growths, contact dermatitis, itchy rashes, minor injury to a limb, psoriasis, scalp rash and skin cyst among the conditions Francesca Walker treats.

CMS data shows 476 Medicare services from Francesca Walker across 6 procedure codes in 2024, for 154 Medicare patients. Medicare paid $15,620 for them. Every service was in an office.

CMS counts 154 Medicare patients who saw Francesca Walker in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 1.02, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Francesca Walker's median patient age at 66, with 63% women.

In 2024, Francesca Walker wrote 1,016 Medicare Part D claims for 446 patients. 94% of them were for generic drugs. CMS names the drug for 918 of them, across 17 drugs with 11 or more claims each, at $91,034 in total drug cost.

Francesca Walker accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 184 general payments to Francesca Walker from 18 drug and device companies in 2025. Food and beverage make up the largest share, 98% of the total. UCB, Inc. paid the most, $479.